Business Wire

MD-ZEROFOX

26.4.2021 15:02:10 CEST | Business Wire | Press release

Share
ZeroFOX Embraces Partner-First Strategy to Further Accelerate Rapid Growth, Launches New Global Partner Program

ZeroFOX , leader in External Threat Intelligence and Protection, today announced the launch of the ZeroFOX Global Partner Program , a strategic pivot to a partner-first strategy. This move significantly increases ZeroFOX’s investment in partner enablement and commitment to conducting all business with and through their full partner ecosystem.

Another leap forward following the company’s significant expansion of cyber threat intelligence capabilities and addition of three 24/7 global security operations centers (SOCs), ZeroFOX’s partner-first strategy will accelerate capabilities for new and existing customers. Supported by a three-tier structure with escalating benefits, including graduating sales incentives, white glove support and marketing development funds, the Global Partner Program also offers a comprehensive go-to-market toolbox to meet the on-demand needs of a global salesforce. Specialized, entrepreneurial partner organizations with access to strategic geographic and vertical markets will be supported through an incubator program that incentivizes successful marketing initiatives, achieving training goals and overall business velocity.

Gartner forecasts that worldwide IT spending will increase 6.2% this year compared to last, reaching $3.9 trillion. Amid this tech growth, businesses are re-examining their cybersecurity approach. In fact, over half (55%) of tech and security executives plan to increase their cyber budgets this year, according to a recent PwC survey . With remote work and digital dependency – including an influx in social media use driven by the pandemic – contributing directly to this rise in attacks, it’s essential that the cybersecurity industry works to drive resiliency across markets.

“Our partners rely on ZeroFOX’s unmatched pace of innovation and commitment to delivering the world’s strongest external threat intelligence service. Together, we have put ourselves in a position to deliver unrivaled protection, intelligence, and disruption capabilities to all of our customers,” said James C. Foster, CEO of ZeroFOX . “Furthermore, our customers appreciate that as a partner-first organization, we invest in differentiated partner solutions. Our AI platform is a true difference maker for our partners and customers alike.”

With ZeroFOX’s Global Partner Program, partners and MSSPs seeking to increase customer value will be provided a rich set of professional services capabilities that ultimately enrich their core offering. To lead the charge, ZeroFOX has hired a full global partnerships team of channel veterans, including a dedicated team of channel partner directors, solution engineers and marketing experts, led by ZeroFOX Vice President of Global Partnerships, Brian Costello.

“ZeroFOX’s investment in enabling partners through sales, marketing, and technical expertise means that our partners can go-to-market faster, drive more demand, and secure more sustainable sources of revenue,” said Brian Costello, Vice President of Global Partnerships at ZeroFOX . “Both on-demand and white glove programs mean partners can confidently project the value that ZeroFOX brings to their portfolio.”

ZeroFOX expects to double partner contribution to the business this year, already acquiring the company’s largest customer in company history through a partner-based contract. Partners continue to broaden ZeroFOX’s capabilities into several verticals targeted widely by cyber criminals, including healthcare and financial services, and extend the company’s geographic footprint and expansion in EMEA, APAC and LATAM.

“ZeroFOX’s ability to bridge social, mobile, surface, and deep and dark web environments delivers a powerful digital risk protection solution in line with Exclusive Networks UK’s ethos of enabling our Partners to differentiate themselves through innovation and addressing the new challenges faced by end users,” said Mark Parr, Director of Strategic Vendors at Exclusive Networks UK . “Our partnership with ZeroFOX has helped drive growth and uncover new opportunities alongside our diverse range of partners. Furthermore, ZeroFOX's integrations with several of our existing technologies results in the creation of comprehensive and scalable solutions to be adopted by our broad partner base. The synergy between Exclusive Networks UK and ZeroFOX extends beyond technology with both organizations leading with a ‘can do’ approach and continually striving to innovate. This makes working together a natural choice.”

To find out more information about ZeroFOX, please visit our website at www.zerofox.com .

About ZeroFOX – ZeroFOX provides enterprises protection, intelligence and disruption to dismantle external threats to brands, people, assets and data across the public attack surface in one, comprehensive platform. With complete global coverage across the surface, deep and dark web and an Intel-backed artificial intelligence-based analysis engine, the ZeroFOX Platform identifies and remediates targeted phishing attacks, credential compromise, data exfiltration, brand hijacking, executive and location threats and more. The patented ZeroFOX Platform technology processes and protects millions of posts, messages and accounts daily across the social and digital landscape, spanning LinkedIn, Facebook, Slack, Instagram, Pastebin, YouTube, mobile app stores, domains, cloud-based email and more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye